Activity Description

In 15 minutes, you can watch this on-demand, case discussion about Summer from the proceedings of a Women’s Health Issues CE course held on April 30, 2016, in Pasadena, California. Learn about:

• The safety and efficacy of long-acting reversible contraception (LARC)
• Individualization of treatment based on the US MEC guidelines and patient preference

 

Learning Objectives

Upon completion of this activity, learners should be able to:

• Evaluate the safety and efficacy of currently available LARC methods
• Individualize LARC management for women based on US MEC guidelines and patient preference

 

Faculty

Suzanne L. Reiter, MSN, MM, WHNP-BC, FAANP

Advanced Registered Nurse Practitioner Specialist

Mid-County Health Center

Largo, FL 

 

Faculty Biography

Suzanne L. Reiter, MSN, MM, WHNP-BC, FAANP 

Suzanne L. Reiter, MSN, MM, WHNP-BC, FAANP, is an ARNP Specialist at the Mid-County Health Center in Largo, Florida. Ms Reiter earned her BSN at the University of Kentucky in Lexington and MSN from Case Western Reserve University in Cleveland, Ohio. She also completed a Master of Management degree from Aquinas College in Grand Rapids, Michigan.

Ms Reiter’s clinical interests include women’s health across a lifespan and long-acting reversible contraception (LARC). She has been the Principal Investigator for 11 research studies involving various aspects of contraception, gynecology, adolescent services, and sexual assault. Ms Reiter has published several scientific journal articles and book chapters in these areas, and has been involved in the development of Women’s Health Nurse Practitioner (WHNP) guidelines for practice and education, contraception, and perimenopause and menopause. Ms Reiter has lectured extensively nationwide on contraception methods, menopausal and postmenopausal topics, and sexual assault. She has served on several boards of directors including the National Association of Nurse Practitioners in Women’s Health and the National Certification Corporation (NCC) for neonatal, obstetric, and gynecologic nursing specialties. Ms Reiter is a Past President of NCC and continues to work on the WHNP Content Team. She was inducted as a Fellow of the American Association of Nurse Practitioners in 2009. For her work in women’s health, Ms Reiter received the Alumni Clinical Practice Award from the University of Kentucky School of Nursing.

 

Disclosure Statements

Nurse Practitioners in Women’s Health (NPWH) policy requires all faculty to disclose any affiliation or relationship with a commercial interest that may cause a potential, real, or apparent conflict of interest with the content of a CE program. NPWH does not imply that the affiliation or relationship will affect the content of the CE program. Disclosure provides participants with information that may be important to their evaluation of an activity. 

 

Conflicts of interest were resolved according to NPWH policy prior to development of content. 

 

NPWH policy requires authors to disclose to the participant when presenting information about unlabeled use of any commercial product or device or an investigational use of a drug or device not yet approved for any use. 

 

Faculty

Suzanne L. Reiter, MSN, MM, WHNP-BC, FAANP 

Consultant/Advisory Board: Actavis Pharma, Inc; Hologic, Inc.

 

Educational Planning Committee

Spire Learning

Jaime Symowicz, PhD, Lauren Waters, and Lisa Conklin have nothing to disclose.

 

National Association of Nurse Practitioners in Women’s Health

Gay Johnson and Susan Rawlins, MS, WHNP-BC, NP, have nothing to disclose. 

 

Disclaimer

The participating faculty determines the editorial content of the CE activity and the content does not necessarily represent the views of NPWH or Spire Learning. This content has been peer reviewed for validation of clinical content. While every effort has been made to ensure that the information is accurate, clinicians are responsible for evaluating this information in relation to generally accepted standards in their own communities and integrating the information in this activity with those of established recommendations of other authorities, national guidelines, FDA-approved package inserts, and individual patient characteristics. 

 

 

Off-label Statement 

This educational activity does not contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

 

Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

 

Levels of Evidence 

The following levels of evidence are provided for any patient care recommendations made in this presentation and are denoted by a superscript A, B, or C. 

 

 

Strength of Recommendation

• Level A: supported by sufficient, consistent scientific evidence (eg, multiple, randomized clinical trials or meta-analyses)
• Level B: supported by limited or inconsistent evidence (eg, nonrandomized trials or single randomized trial)
• Level C: based primarily on expert opinion